- PR Newswire•21 minutes ago
European Commission Approves AMGEVITA™ (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases
THOUSAND OAKS, Calif., March 23, 2017 /PRNewswire/ -- Amgen (AMGN) today announced that the European Commission (EC) has granted marketing authorization for AMGEVITA™ (biosimilar adalimumab1) in all available indications. The EC also approved AMGEVITA for the treatment of certain pediatric inflammatory diseases, including moderate-to-severe Crohn's disease (ages six and older), severe chronic plaque psoriasis (ages four and older), enthesitis-related arthritis (ages six and older) and polyarticular juvenile idiopathic arthritis (ages two and older).
- Investor's Business Daily•2 hours ago
Regeneron expects to top Amgen's recent heart-drug study in a team-up with Sanofi.
- Motley Fool•7 hours ago
The Medicines Company is developing a new drug that could give Amgen's Repatha a run for its money in lowering bad cholesterol levels.
AMGN : Summary for Amgen Inc. - Yahoo Finance
Amgen Inc. (AMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||165.44 x 100|
|Ask||167.29 x 100|
|Day's Range||165.57 - 167.98|
|52 Week Range||133.64 - 184.21|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||16.21|
|Dividend & Yield||4.60 (2.76%)|
|1y Target Est||N/A|